Filing Flows › Comparisons › CHRS vs CRSP
Coherus Oncology vs Crispr Therapeutics AG: CHRS and CRSP compared
Coherus Oncology is the larger company: $14.3M of revenue in its latest quarter (Q2 2026) against $12.7M for Crispr Therapeutics AG (Q3 2026). Crispr Therapeutics AG is growing faster (14× against +40% a year earlier).
Where the money goes: CHRS and CRSP
Coherus Oncology (CHRS) · Q2 2026
Coherus Oncology, Q2 2026: revenue $14.3M (+40% year over year), operating margin -226.0%, net loss $20.6M, operating cash flow −$62.1M. The chart follows the revenue to costs, profit and cash.
Crispr Therapeutics AG (CRSP) · Q3 2026
Crispr Therapeutics AG, Q3 2026: revenue $12.7M (14× year over year), net loss $111M, operating cash flow −$89.7M. The chart follows the revenue to costs, profit and cash.
| Coherus Oncology (CHRS) | Crispr Therapeutics AG (CRSP) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q3 2026 |
| Revenue | $14.3M | $12.7M |
| Revenue growth, Y/Y | +40% | 14× |
| Operating margin | -226.0% | n/m |
| Net earnings | −$20.6M | −$111M |
| Net margin | -144.2% | -879.6% |
| Operating cash flow | −$62.1M | −$89.7M |
Where the revenue comes from
Coherus Oncology
- Toripalimab: $13.6M (95%)
- Other revenue: $694K (5%)
Crispr Therapeutics AG
- Collaboration Revenue: $12.3M (97%)
- Grant: $346K (3%)
Questions
Which is bigger, Coherus Oncology or Crispr Therapeutics AG?
Coherus Oncology is the larger company: $14.3M of revenue in its latest quarter (Q2 2026) against $12.7M for Crispr Therapeutics AG (Q3 2026).
Is Coherus Oncology or Crispr Therapeutics AG growing faster?
Crispr Therapeutics AG is growing faster (14× against +40% a year earlier).
More: Coherus Oncology earnings · how Coherus Oncology makes money · Crispr Therapeutics AG earnings · how Crispr Therapeutics AG makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 5, 2026; 10-Q filed Nov 2, 2026). Fiscal quarters can end on different dates. Not investment advice.